Variable | SLE-CSQ score | OR | 95% interval | P value |
Haemoglobin (g/L) | 0 | 1.58 | 1.47 to 1.72 | <0.0001 |
1 | 1.20 | 1.10 to 1.31 | <0.0001 | |
2–3 | 1.06 | 0.97 to 1.16 | 0.19 | |
≥4 | Ref | |||
Leucocytes (×109/L), log-transformed | 0 | 0.72 | 0.45 to 1.15 | 0.17 |
1 | 0.66 | 0.41 to 1.07 | 0.09 | |
2–3 | 0.51 | 0.32 to 0.84 | 0.007 | |
≥4 | Ref | |||
Neutrophils (×109/L), log-transformed | 0 | 0.69 | 0.48 to 0.98 | 0.04 |
1 | 0.65 | 0.46 to 0.93 | 0.02 | |
2–3 | 0.56 | 0.39 to 0.80 | 0.002 | |
≥4 | Ref | |||
Monocytes (×109/L), log-transformed | 0 | 0.83 | 0.55 to 1.25 | 0.38 |
1 | 0.82 | 0.55 to 1.24 | 0.35 | |
2–3 | 0.71 | 0.47 to 1.07 | 0.10 | |
≥4 | Ref | |||
Thrombocytes (×109/L), log-transformed | 0 | 0.85 | 0.49 to 1.47 | 0.56 |
1 | 0.95 | 0.55 to 1.65 | 0.86 | |
2–3 | 1.03 | 0.59 to 1.80 | 0.93 | |
≥4 | Ref | |||
Creatinine (nmol/L), square root-transformed | 0 | 1.04 | 0.95 to 1.14 | 0.35 |
1 | 1.04 | 0.95 to 1.14 | 0.39 | |
2–3 | 0.97 | 0.91 to 1.09 | 0.97 | |
≥4 | Ref | |||
CTD screen-positive | 0 | 0.77 | 0.48 to 1.25 | 0.29 |
1 | 0.95 | 0.61 to 1.59 | 0.95 | |
2–3 | 0.70 | 0.56 to 1.49 | 0.70 | |
≥4 | Ref | |||
Women only | ||||
Nulliparous (yes) | 0 | 0.75 | 0.65 to 0.87 | <0.001 |
1 | 0.80 | 0.80 to 0.69 | 0.003 | |
2–3 | 1.00 | 0.86 to 1.15 | 0.96 | |
≥4 | Ref | |||
Menopausal (yes) | 0 | 1.31 | 1.07 to 1.59 | 0.009 |
1 | 1.01 | 0.87 to 1.31 | 0.52 | |
2–3 | 1.02 | 0.83 to 1.25 | 0.88 | |
≥4 | Ref | |||
Current OCP use (yes) | 0 | 1.26 | 1.12 to 1.42 | <0.001 |
1 | 1.24 | 1.10 to 1.14 | <0.001 | |
2–3 | 1.13 | 1.00 to 1.27 | 0.04 | |
≥4 | Ref | |||
OCP use, ever (yes) | 0 | 0.66 | 0.55 to 0.80 | <0.001 |
1 | 0.83 | 0.69 to 1.00 | 0.05 | |
2–3 | 1.09 | 0.90 to 1.31 | 0.40 | |
≥4 | Ref |
P values ≤0.05 are considered significant.
BMI, body mass index; CTD, connective tissue disease; OCP, oral anticonceptive pills; Ref, reference; SLE-CSQ, Connective Tissue Disease Screening Questionnaire focusing on SLE.